Home › RLT targets by cancer › Kidney Cancer
Radioligand therapy · Kidney Cancer

Radioligand Therapy Targets in Kidney Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in kidney cancer (including clear cell renal cell carcinoma (ccRCC)). 4,078 show detectable protein staining. Established and emerging radioligand targets expressed in kidney cancer include EGFR, HER3 (ERBB3), c-MET (MET) and ITGAV. Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own kidney cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank kidney cancer targets free

Established and emerging radioligand targets in kidney cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in kidney cancer:

TargetIHC in kidney cancer% positiveInternalizes
EGFRHigh (0.85)100%yes
HER3 (ERBB3)High (0.72)100%yes
c-MET (MET)High (0.72)100%yes
ITGAVHigh (0.61)92%—
STEAP2High (0.58)100%—
CAIX (CA9)Medium (0.31)50%no
B7-H3 (CD276)Low (0.17)50%—
Mesothelin (MSLN)Low (0.15)18%yes
Nectin-4 (NECTIN4)Low (0.11)33%no
TMEFF2Low (0.11)25%—
SSTR2Low (0.06)18%yes
HER2 (ERBB2)Low (0.06)17%yes
FAPLow (0.03)9%yes
EPCAMLow (0.03)8%—
ITGB6Low (0.03)8%—

Top cell-surface targets for kidney cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in kidney cancer% positiveInternalizesClinical stage
1EGFR
epidermal growth factor receptor
High (0.85)100%yesFDA-Approved
2c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.72)100%yesFDA-Approved
3HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.72)100%yesFDA-Approved
4MAOB
monoamine oxidase B
High (1.00)100%—FDA-Approved
5IGF1R
insulin like growth factor 1 receptor
High (0.69)100%yesFDA-Approved
6AMFR
autocrine motility factor receptor
High (0.94)100%yesDiscovery
7S1PR1
sphingosine-1-phosphate receptor 1
High (0.53)83%yesFDA-Approved
8GPR139
G protein-coupled receptor 139
High (0.91)100%yesDiscovery
9M6PR
mannose-6-phosphate receptor, cation dependent
High (0.89)100%yesDiscovery
10GABRE
gamma-aminobutyric acid type A receptor subunit epsilon
High (0.94)100%uncertainFDA-Approved
11AGTRAP
angiotensin II receptor associated protein
High (0.83)100%yesDiscovery
12SMOX
spermine oxidase
High (0.97)100%uncertainDiscovery
13NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.72)100%uncertainFDA-Approved
14TREM1
triggering receptor expressed on myeloid cells 1
High (0.81)100%uncertainClinical
15CCND1
cyclin D1
High (0.97)100%—FDA-Approved
16PTPN22
protein tyrosine phosphatase non-receptor type 22
High (0.76)100%yesDiscovery
17APH1A
aph-1A gamma-secretase subunit
High (0.97)100%—FDA-Approved
18RNF43
ring finger protein 43
High (0.97)100%—Discovery
19HTR6
5-hydroxytryptamine receptor 6
Medium (0.42)91%yesFDA-Approved
20TLR3
toll like receptor 3
High (0.69)100%uncertainClinical
21CYSLTR2
cysteinyl leukotriene receptor 2
High (0.58)92%yesDiscovery
22NOTCH1
notch receptor 1
High (0.53)100%yesClinical
23LHCGR
luteinizing hormone/choriogonadotropin receptor
Medium (0.48)91%yesFDA-Approved
24IL1R2
interleukin 1 receptor type 2
High (0.56)92%yesDiscovery
25FZD3
frizzled class receptor 3
High (0.69)100%yesDiscovery

Internalizing receptors in kidney cancer

Targets expressed in kidney cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

EGFR · c-MET (MET) · HER3 (ERBB3) · IGF1R · AMFR · S1PR1 · GPR139 · M6PR · AGTRAP · PTPN22 · HTR6 · CYSLTR2

Kidney Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in kidney cancer. Clinical precedent lowers development risk but usually means more competition:

EGFR · c-MET (MET) · HER3 (ERBB3) · MAOB · IGF1R · S1PR1 · GABRE · NR3C2 · TREM1 · CCND1 · APH1A · HTR6

How these kidney cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in kidney cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank kidney cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free kidney cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist kidney cancer targets for your program · 5 free analyses, no card Rank kidney cancer targets free